The trial’s first phase will begin in university hospitals across the Netherlands, Denmark, Germany and Sweden.

European regulators have cleared Anocca to begin a Phase I/II umbrella trial of its lead targeted T-cell receptor (TCR) therapy ANOC-001 and other pipeline candidates in certain advanced pancreatic ...

Anocca has achieved regulatory approval for its first clinical trial, VIDAR-1, a major milestone in the company’s transition ...

SAN FRANCISCO, March 17, 2025 (GLOBE NEWSWIRE) -- c/side, a cybersecurity company specializing in browser-side third-party scripts, is now available in AWS Marketplace, a digital catalog with ...

CTA approval marks Anocca’s transition to a clinical-stage companyFirst-in-human VIDAR-1 trial begins with the deployment of ...

Microbiotica, a clinical-stage biopharma company, has presented new data on MB097 at the AACR IO meeting held in Los Angeles. MB097 is an oral precision microbiome medicine, currently in development ...

NEW YORK – The UK's National Institute for Health and Care Excellence (NICE) on Friday approved Amgen's Blincyto (blinatumomab) with chemotherapy as a consolidation treatment for adult patients with ...